This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix prices initial public offering at $13 per share

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ocular Therapeutix has priced its initial public offering of 5,000,000 common stock shares at $13 per share, before underwriting discounts and commissions, according to a company press release.

The company has also granted the underwriters an option for a 30-day purchase period at the public offering price excluding the underwriting discount — up to 750,000 additional shares of common stock to cover over-allotments, according to the press release.

Joint book-running managers of the offering include Morgan Stanley & Co., Cowen and Company and RBC Capital Markets.